KLOW
Intermediate FriendlyWhat does the TB-500, GHK-Cu, KPV and BPC-157 protocol include?
This 8-week protocol combines TB-500, GHK-Cu, KPV, and BPC-157 in a structured three-phase schedule focused on tracking changes in skin appearance over time. The protocol begins with an Initiation phase, progresses into Therapeutic Renewal, and then continues into Consolidation & Radiance. The schedule gradually increases the published GHK-Cu amount while maintaining the published schedule for the other three peptides. All four peptides are included during each phase and follow a five-days-per-week morning schedule. Each published phase also includes a 14-day hold period. Review the individual research, safety information, peptide details, amounts, timing, and phase structure before following any schedule. The published stack should be reviewed as a starting structure rather than treated as an automatically selected personal plan.
Overview
Combines four complementary peptides in a structured 8-week protocol focused on skin appearance and recovery support. The stack brings together components associated with tissue remodeling, skin structure, inflammatory balance, and recovery in three progressive phases.
Stack Synergy
KLOW combines four peptides with complementary roles in one structured skin-focused protocol. TB-500 provides the rebuilding component of the stack and is positioned around recovery and tissue remodeling. GHK-Cu provides the structural and skin-focused component, supporting the protocol's emphasis on skin appearance and progressive renewal. KPV adds the calming component of the stack, complementing the broader structure with an inflammation-focused role. BPC-157 provides the recovery-oriented component and complements the other peptides through its role within the protocol's healing and repair structure. Together, the four components create a phased protocol organized around rebuilding, structural support, inflammatory balance, and recovery. These role labels describe how the published stack is structured and do not establish that the full combination is safe or effective.
Benefits
Peptides in This Protocol
Planning the source side of a stack? Compare current peptide prices by vial size before reviewing individual peptide profiles.
TB-500
GHK-Cu
KPV
BPC-157
Phase Timeline
Initiation
Days 1–7 14 daysFollow the published five-days-per-week morning schedule and review individual peptide details and response before progressing to the next phase.
Therapeutic Renewal
Days 8–14 14 daysContinue the five-days-per-week morning schedule and review the published amount changes before moving into the final phase.
Consolidation & Radiance
Days 15–56 14 daysContinue the published five-days-per-week morning schedule through Day 56 and review the complete cycle before beginning the listed hold period.
Who Is This For
Intermediate Level KLOW is structured as an intermediate-level protocol for people interested in tracking changes in skin appearance through a multi-peptide, phased schedule. The protocol may appeal to users looking for a structured approach that combines skin-focused components with recovery, tissue remodeling, and inflammation-focused considerations. Because KLOW combines four peptides and progresses through three phases over eight weeks, users should be comfortable reviewing multiple peptide schedules and phase changes before following the complete structure. Before following any peptide protocol, review the individual research, safety information, amounts, timing, and personal considerations for every peptide included.
More questions about this schedule
What peptides are included in KLOW?
The published KLOW Stack includes four peptides: TB-500, GHK-Cu, KPV, and BPC-157.
How long is the KLOW protocol?
The published KLOW Stack runs for 8 weeks, covering Days 1 through 56.
How many phases are included in KLOW?
The published schedule contains three phases: Initiation, Therapeutic Renewal, and Consolidation & Radiance.
Do all four peptides appear in every phase?
Yes. The published schedule includes TB-500, GHK-Cu, KPV, and BPC-157 in each of the three phases, with changes to some published amounts as the protocol progresses.
How often are the peptides scheduled?
The published KLOW schedule lists all four peptides five days per week during each active phase.
